BackActuate Therapeutics Overview

Actuate Therapeutics Total Current Liabilities

Track Actuate Therapeutics's total current liabilities ($3.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$3.81M
↓ 58.64% YoYΔ $-5.40M vs prior year quarter

Peer trimmed avg / median

Loading

Actuate Therapeutics Total Current Liabilities History

Loading

Actuate Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

Actuate Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Actuate Therapeutics (ACTU) FAQ

Actuate Therapeutics posts a total current liabilities of $3.8M as of June 2026. That compares with $9.2M in the prior-year period — down 58.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Actuate Therapeutics's total current liabilities was $9.2M. The latest reading is $3.8M — a 58.6% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of Actuate Therapeutics's financial statement story. At $3.8M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ACTU's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Actuate Therapeutics's other metric pages and overview cover the third.